Rybelsus®

Semaglutide

Rybelsus® tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus® can be prescribed when other diabetes medicines have been tried without success and should be used together with diet and exercise. Rybelsus® tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating.
more
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
QAR 54.67
QAR 4920.30QAR 54.67
QAR 655.70
60 tablet
Free AirMail shipping Hot
QAR 58.31
QAR 3498.83QAR 58.31
QAR 218.51
30 tablet
Free AirMail shipping Hot
QAR 61.96
QAR 1858.67QAR 61.96
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
QAR 65.60
QAR 5904.39QAR 65.60
QAR 327.67
60 tablet
Free AirMail shipping Hot
QAR 67.43
QAR 4045.55QAR 67.43
QAR 109.16
30 tablet
Free AirMail shipping Hot
QAR 69.25
QAR 2077.35QAR 69.25
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
QAR 78.36
QAR 7052.51QAR 78.36
QAR 327.67
60 tablet
Free AirMail shipping Hot
QAR 80.18
QAR 4810.95QAR 80.18
QAR 109.16
30 tablet
Free AirMail shipping Hot
QAR 82.00
QAR 2460.06QAR 82.00
Rybelsus

Brand(s)

Manufacturer

  • Novo Nordisc India Pvt. Ltd

Disease(s)

  • Type 2 Diabetes Mellitus / High Blood Sugar

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.